October 30, 2024
Data Presented at TCT Reinforce Edwards Lifesciences’ Commitment to Structural Heart Innovation
Press releases
October 30, 2024
TRISCEND II Trial Demonstrates Superior Clinical and Quality-of-life Benefits With Edwards EVOQUE System for Severe Tricuspid Regurgitation
October 28, 2024
Groundbreaking Data Demonstrate Superiority of EARLY TAVR in Asymptomatic Severe Aortic Stenosis Patients
August 31, 2024
First All-Female TAVI Trial Shows Excellent Outcomes for Women Receiving Edwards Valves
August 21, 2024
Edwards Lifesciences to Present at the 2024 Wells Fargo Healthcare Conference
July 24, 2024
Edwards Lifesciences Expands Structural Heart Portfolio With Acquisitions of JenaValve and Endotronix
June 05, 2024
Five-Year Data Show Excellent Outcomes for Female and Small Annulus Patients With Edwards TAVR
May 08, 2024
Edwards Launches the SAPIEN 3 Ultra RESILIA Valve in Europe With Technology to Enhance Durability
April 07, 2024
Study of NFL Alumni Cohort Finds Majority Suffer From Heart Disease Without Knowing It
March 11, 2024
Large, Real-world Studies Demonstrate Continued Excellent Outcomes for Patients Receiving Edwards SAPIEN TAVR
February 23, 2024
Edwards Lifesciences to Present at the 44th Annual TD Cowen Healthcare Conference
February 02, 2024
Edwards’ EVOQUE Valve Replacement System First Transcatheter Therapy to Earn FDA Approval for Tricuspid Valve
January 02, 2024
Edwards Lifesciences to Present at the 42nd Annual J.P. Morgan Healthcare Conference
December 07, 2023
EDWARDS LIFESCIENCES OUTLINES GROWTH STRATEGY AT ANNUAL INVESTOR CONFERENCE
October 26, 2023
CLASP IID ONE-YEAR DATA CONFIRM SAFETY AND EFFICACY OF EDWARDS PASCAL SYSTEM FOR DEGENERATIVE MITRAL REGURGITATION
October 26, 2023
TRISCEND II SIX-MONTH DATA FOR FIRST 150 PATIENTS SUCCESSFULLY DEMONSTRATE SAFETY AND EFFICACY OF EDWARDS EVOQUE SYSTEM FOR SEVERE TRICUSPID REGURGITATION
October 24, 2023
FIVE-YEAR DATA FROM PARTNER 3 TRIAL DEMONSTRATE EXCELLENT SURVIVAL FOR PATIENTS RECEIVING EDWARDS SAPIEN 3 VALVE
October 19, 2023
EDWARDS EVOQUE TRANSCATHETER TRICUSPID VALVE REPLACEMENT SYSTEM RECEIVES CE MARK
August 28, 2023
EDWARDS LIFESCIENCES TO PRESENT AT THE 2023 WELLS FARGO HEALTHCARE CONFERENCE
May 17, 2023
DATA FROM BENCHMARK REGISTRY DEMONSTRATE IMPROVED TAVR EFFICIENCY WITH PRESERVED PATIENT SAFETY
May 08, 2023
EDWARDS' AORTIC VALVE WITH RESILIA TISSUE SHOWS FAVORABLE DURABILITY, SAFETY AND EFFICACY OUTCOMES IN SEVEN YEAR DATA
March 06, 2023
EDWARDS HIGHLIGHTS NEW DATA AT ACC RELATED TO LIFETIME MANAGEMENT OF AORTIC STENOSIS
January 05, 2023
EDWARDS LIFESCIENCES TO PRESENT AT THE 41ST ANNUAL J.P. MORGAN HEALTHCARE CONFERENCE
December 08, 2022
EDWARDS LIFESCIENCES OUTLINES GROWTH STRATEGY AT ANNUAL INVESTOR CONFERENCE
November 27, 2022
EDWARDS ANNOUNCES ONE-YEAR DATA ON TRANSFEMORAL TRANSCATHETER TRICUSPID VALVE REPLACEMENT
September 17, 2022
EDWARDS ANNOUNCES SIX-MONTH DATA CONFIRMING TEER AS SAFE AND EFFECTIVE FOR DMR IN FIRST HEAD-TO-HEAD TRIAL
September 15, 2022
EDWARDS PASCAL PRECISION TRANSCATHETER VALVE REPAIR SYSTEM RECEIVES FDA APPROVAL FOR DEGENERATIVE MITRAL REGURGITATION
August 17, 2022
EDWARDS PASCAL PRECISION TRANSCATHETER MITRAL AND TRICUSPID VALVE REPAIR SYSTEM RECEIVES CE MARK
May 23, 2022
EDWARDS LIFESCIENCES TO PRESENT AT THE BERNSTEIN 38TH ANNUAL STRATEGIC DECISIONS CONFERENCE
March 31, 2022
EDWARDS MITRIS RESILIA VALVE RECEIVES FDA APPROVAL FOR MITRAL REPLACEMENT SURGERIES
January 05, 2022
EDWARDS LIFESCIENCES TO PRESENT AT THE 40TH ANNUAL J.P. MORGAN HEALTHCARE CONFERENCE
December 20, 2021
EDWARDS RECEIVES FDA APPROVAL FOR SAPIEN 3 WITH ALTERRA PRESTENT FOR TRANSCATHETER PULMONIC VALVE REPLACEMENT
December 08, 2021
Edwards Lifesciences Outlines Growth Strategy at Annual Investor Conference
November 06, 2021
Edwards Announces Six-month Data From Transcatheter Tricuspid Replacement Program
November 05, 2021
TAVR with SAPIEN 3 Demonstrated as Economically Dominant Treatment Strategy Compared to Surgery in Partner 3 Analysis
August 02, 2021
Edwards Lifesciences initiates $100 million social impact investment fund to advance racial equity
July 22, 2021
Study Data Presented at TVT on the Economics of Minimalist TAVR, PARTNER 3 Bicuspid TAVR
June 01, 2021
Edwards Receives Clearance For Hypotension Prediction Index Software For Noninvasive Acumen IQ Cuff
May 18, 2021
Clinical Data Updates On Edwards' Transcatheter Mitral, Tricuspid Programs Presented At EuroPCR
May 18, 2021
Real-World Data Confirm Excellent Results For Bicuspid Patients Treated With Edwards SAPIEN 3 TAVR
January 31, 2021
Edwards RESILIA Tissue Aortic Valve Demonstrates Favorable Safety and Efficacy at Five Years
December 21, 2020
Edwards Treats First Patient In U.S. Clinical Trial Evaluating Minimally Invasive Device For Mitral Valve Disease
December 10, 2020
Edwards Lifesciences Outlines Growth Strategy At Annual Investor Conference
July 15, 2020
Edwards' KONECT RESILIA Aortic Valved Conduit Receives FDA Approval For Complex Aortic Valve Surgeries
July 13, 2020
Edwards Lifesciences Agrees To Global Transcatheter Litigation Settlement With Abbott
May 18, 2020
Edwards PASCAL Transcatheter Valve Repair System Receives European Approval For Tricuspid Repair
March 28, 2020
Edwards Pauses Enrollments In Pivotal Mitral, Tricuspid Trials In Response To Hospitals' Focus On COVID-19
February 24, 2020
Edwards Lifesciences To Present At The Cowen 40th Annual Healthcare Conference
February 21, 2020
Edwards Lifesciences' Every Heartbeat Matters Philanthropic Initiative Expanding To Reach More Patients
January 08, 2020
Edwards Lifesciences To Present At The 38th Annual J.P. Morgan Healthcare Conference
December 05, 2019
Edwards Lifesciences Outlines Growth Strategy At Annual Investor Conference
September 29, 2019
Edwards SAPIEN 3 TAVR Demonstrates Significant Health Status Improvements for Low-Risk Patients
August 28, 2019
Edwards Lifesciences To Present At The 2019 Wells Fargo Healthcare Conference
June 04, 2019
Edwards Lifesciences To Present At The Goldman Sachs 40th Annual Global Healthcare Conference
June 03, 2019
Edwards Lifesciences Recommends Stockholders Reject "Mini-Tender Offer" By TRC Capital Corporation
May 15, 2019
Edwards Lifesciences' Every Heartbeat Matters Charitable Initiative On Track to Impact 1.5 Million Underserved People By 2020
May 07, 2019
Favorable Study Outcomes Presented On Edwards Aortic Valves With RESILIA Tissue
January 15, 2019
Boston Scientific, Edwards Lifesciences Agree To Global Litigation Settlement
December 05, 2018
Edwards Lifesciences Outlines Growth Strategy At Annual Investor Conference
December 03, 2018
Edwards Receives Clearance For HemoSphere Platform With Intelligent Decision-Support Tools
October 08, 2018
Edwards Announces Start Of U.S. Study Of Self-Expanding Transcatheter Heart Valve
September 26, 2018
Edwards Lifesciences' Philanthropy Exceeds Every Heartbeat Matters Goal To Impact One Million Underserved People Ahead Of Schedule
August 30, 2018
Edwards Lifesciences To Present At The 13th Annual Wells Fargo Healthcare Conference
August 02, 2018
Edwards Lifesciences To Present at 38th Annual Canaccord Genuity Growth Conference
May 24, 2018
Edwards Lifesciences To Present At The Bernstein 34th Annual Strategic Decisions Conference
May 22, 2018
Real-World Evidence Confirms Clinical Trial Outcomes For Patients Treated With Edwards SAPIEN 3 Valve
March 23, 2018
Edwards Prevails In U.S. Patent Office Review That Finds Boston Scientific Transcatheter Valve Patent Claims Invalid
March 21, 2018
Edwards Completes Enrollment In PARTNER 3 Low-Risk CT Sub-Study, Updates Timeline For SAPIEN 3 Ultra System Launch In Europe
March 06, 2018
Edwards Lifesciences To Present At The Cowen 38th Annual Health Care Conference
January 02, 2018
Edwards Lifesciences To Present At The 36th Annual J.P. Morgan Healthcare Conference
Contacts
Investors
Mark Wilterding
(SVP, Investor Relations)
Media
Amy Hytowitz
(VP, Global Communications)